A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Conditions

• Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)
• Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
• Cohort 3a and 3b: Chondrosarcoma
• Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
• Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations

Interventions

• DRUG: FT-2102
• DRUG: Azacitidine
• BIOLOGICAL: Nivolumab
• DRUG: Gemcitabine and Cisplatin

Sponsor

Forma Therapeutics, Inc.